What BioAge's Upsized IPO Tells Us About The Obesity Trend
In recent days, obesity drug developer BioAge became the latest biotech to test the public waters. The firm's $198 million upsized offering signals a continued interest in the obesity market as...To view the full article, register now.
Already a subscriber? Click here to view full article